Regenera receives ethics approval for second clinical trial

By Renate Krelle
Wednesday, 20 October, 2004

Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.

Visagen is a preservative free formulation of the steroid triamcinolone acetonide.

The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...

Content from other channels on our network

Scooping Up Success: Sajani Cups and Cones Freezes Out Stock Issues with Fishbowl

Managing Food Safety Risk Efficiently with Data Automation

Introducing Tool-Free Mounting and Reduced Service Times with Bürkert's Direct Acting Service Valves

Hygiene-first cables and connectors for the food and beverage industry

Futurecasting Food Science with data

Seamless modular I/O integration

Coca-Cola invests nearly $100 million in Queensland manufacturing

Endress+Hauser receives IEC 62443‍-‍4‍-‍1 cybersecurity certification

NSW announces TAFE Centre of Excellence in the Hunter

CSP to power pet food manufacturing in Wodonga

Medline introduces Namic Ready Set Kits

Solventum innovations enabling better, smarter, safer healthcare

Lumia Care expands national network with SA acquisition

Funding to support cervical cancer screening and treatment in the Pacific

Packaged foods: strict salt targets could prevent 40K cardiovascular events